Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 468

1.

Aspirin overprescription in primary cardiovascular prevention.

Manes C, Giacci L, Sciartilli A, D'Alleva A, De Caterina R.

Thromb Res. 2006;118(4):471-7.

PMID:
16321425
2.

A national survey on aspirin patterns of use and persistence in community outpatients in Italy.

Filippi A, Bianchi C, Parazzini F, Cricelli C, Sessa E, Mazzaglia G.

Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):695-703. doi: 10.1177/1741826710397850. Epub 2011 Mar 1.

PMID:
21450601
3.

Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: lessons learned from a health care services study.

Zachariadou T, Stoffers HE, Christophi CA, Philalithis A, Lionis C.

BMC Health Serv Res. 2008 Jul 16;8:148. doi: 10.1186/1472-6963-8-148.

4.

Consequences of using different methods to assess cardiovascular risk in primary care.

Fornasini M, Brotons C, Sellarès J, Martinez M, Galán ML, Sáenz I, da Pena JM.

Fam Pract. 2006 Feb;23(1):28-33. Epub 2005 Oct 21.

PMID:
16243952
5.

National study of physician awareness and adherence to cardiovascular disease prevention guidelines.

Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, Fabunmi RP, Kwan J, Mills T, Simpson SL.

Circulation. 2005 Feb 1;111(4):499-510.

6.

Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?

Monesi L, Avanzini F, Barlera S, Caimi V, Lauri D, Longoni P, Roccatagliata D, Tombesi M, Tognoni G, Roncaglioni MC.

Eur J Clin Pharmacol. 2005 Sep;61(8):595-601. Epub 2005 Jul 15.

PMID:
16021439
7.

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group.

Diabetes Care. 2003 Dec;26(12):3264-72.

PMID:
14633812
8.

Medical treatment and secondary prevention of coronary heart disease in general practice in Iceland.

Sigurdsson EL, Jónsson JS, Thorgeirsson G.

Scand J Prim Health Care. 2002 Mar;20(1):10-5.

PMID:
12086276
9.

A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.

Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L.

Intern Med. 2007;46(4):157-62. Epub 2007 Feb 15.

10.

Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.

Morimoto T, Fukui T, Lee TH, Matsui K.

Am J Med. 2004 Oct 1;117(7):459-68. Review.

PMID:
15464702
11.
13.

Three years follow-up of screen-detected diabetic and non-diabetic subjects: who is better off? The ADDITION Netherlands study.

Janssen PG, Gorter KJ, Stolk RP, Akarsubasi M, Rutten GE.

BMC Fam Pract. 2008 Dec 16;9:67. doi: 10.1186/1471-2296-9-67.

14.

Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice.

Filippi A, Paolini I, Innocenti F, Mazzaglia G, Battaggia A, Brignoli O.

J Hum Hypertens. 2009 Nov;23(11):758-63. doi: 10.1038/jhh.2009.14. Epub 2009 Feb 26.

PMID:
19242492
16.

[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].

Vanuzzo D, Pilotto L, Mirolo R, Pirelli S.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S. Review. Italian.

PMID:
18773746
17.

Management outcomes of patients with type 2 diabetes: targeting the 10-year absolute risk of coronary heart disease.

Yong TY, Phillipov G, Phillips PJ.

Med J Aust. 2007 Jun 18;186(12):622-4. Erratum in: Med J Aust. 2007 Aug;187(3):152.

PMID:
17576176
18.

A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.

Lamotte M, Annemans L, Evers T, Kubin M.

Pharmacoeconomics. 2006;24(2):155-69.

PMID:
16460136
19.

Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study.

Leung WY, So WY, Stewart D, Lui A, Tong PC, Ko GT, Kong AP, Ma RC, Chan FK, Yang X, Chiang SC, Chan JC.

Cardiovasc Diabetol. 2009 Oct 30;8:57. doi: 10.1186/1475-2840-8-57.

20.

[Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].

Auer J, Berent R, Weber T, Porodko M, Mayr H, Maurer E, Eber B.

Wien Med Wochenschr. 2001;151(1-2):13-7. Review. German.

PMID:
11234591

Supplemental Content

Support Center